Algiax Pharmaceuticals GmbH is an independent biotechnology company that was established in April 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. In the field of nervous system disease, Algiax has a strong focus on neuropathic pain and acute spinal cord injury. Algiax’ lead candidate AP-325 is in clinical development for the treatment of neuropathic pain. A selection of new chemical entities (AP-4 & AP-8) is in preclinical development for the treatment of Diabetes Type 1. Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorisation.